Methods of treating p38 kinase-mediated disorders with pyrido[2,3-d]pyrimidin-7-one compounds

   
   

Disorders mediated by p38 kinase inhibitors are treated with compounds of the formula: ##STR1## or salts thereof, wherein: R.sup.1 is hydrogen or alkyl; R.sup.2 is substituted cycloalkyl, heterosubstituted cycloalkyl, helcroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl-alkly, heterocyclyl, heterocyclyl spiro cycloalkyl, aralkoxy, alkoxy, -alkylene-S(O).sub.n -alkyl (where is 1 or 2) or --SO.sub.2 Ar.sup.2 ; R.sup.3 is hydrogen, amino, monoalkylamino, dialkylamino, acylamino, --NR.sup.8 --C(.dbd.O)--R.sup.b (where R.sup.a is hydrogen or alkyl and R.sup.h is heterocyclyl or heteroalkyl), alkyl, cycloalkyl, phthalimidoalkyl, aryl, aralkyl, haloalkyl, heteroalkyl, cyanoalkyl, -alkylene-C(O) R (where R is hydrogen, alkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino) or acyl; and each of Ar.sup.1 and Ar.sup.2 is independently aryl.

Los desórdenes mediaron por los inhibidores del kinase p38 se tratan con los compuestos del fórmula: ## del ## STR1 o sales de eso, en donde: R.sup.1 es hidrógeno o alkyl; R.sup.2 es cycloalkyl substituido, heterosubstituted cycloalkyl, helcroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl-alkly, heterocyclyl, cycloalkyl del spiro del heterocyclyl, aralkoxy, alkoxy, - alkylene-S(O).sub.n - alkyl (donde está 1 o 2) o -- SO.sub.2 Ar.sup.2; R.sup.3 es hidrógeno, amino, monoalkylamino, dialkylamino, acylamino, -- NR.sup.8 -- C(.dbd.O) -- R.sup.b (donde está hidrógeno R.sup.a o el alkyl y R.sup.h es heterocyclyl o heteroalkyl), alkyl, cycloalkyl, phthalimidoalkyl, aryl, aralkyl, haloalkyl, heteroalkyl, cyanoalkyl, - alkylene-C(O-C(O) R (donde está hidrógeno, alkyl, hydroxy, alkoxy, amino R, monoalkylamino o dialkylamino) o acyl; y cada uno de Ar.sup.1 y de Ar.sup.2 es independientemente aryl.

 
Web www.patentalert.com

< suPAR stimulating activity of tcuPA-mediated fibrinolysis and different uses thereof

< Tissue regenerative composition, method of making, and method of use thereof

> Platelet adenosine diphosphate receptor antagonists

> Human protein HFXJW48

~ 00165